Skip to main content
Top
Published in: BMC Public Health 1/2019

Open Access 01-12-2019 | Contraception | Research article

Perspectives on contraceptive implant use in women living with HIV in Cape Town, South Africa: a qualitative study among primary healthcare providers and stakeholders

Authors: Anna Brown, Jane Harries, Diane Cooper, Chelsea Morroni

Published in: BMC Public Health | Issue 1/2019

Login to get access

Abstract

Background

This study explored primary healthcare provider and HIV/contraception expert stakeholder perspectives on South Africa’s public sector provision of contraceptive implants to women living with HIV. We investigated the contraceptive service-impact of official advice against provision of implants to women using the HIV antiretroviral drug, efavirenz, issued by the South African National Department of Health (NDoH) in 2014.

Methods

Qualitative data was collected in Cape Town in 2017 from primary healthcare contraceptive providers in four clinics that provide implants, as well as from other expert stakeholders selected for expertise in HIV and/or contraception. In-depth interviews and a group discussion explored South Africa’s implant introduction and implant provision to women living with HIV. Data was analysed using an inductive thematic analysis approach.

Results

Interviews were conducted with 10 providers and 10 stakeholders. None of the four clinics where the providers worked currently offered the implant to women living with HIV. Stakeholders confirmed that this was consistent with patterns of implant provision at primary healthcare facilities across Cape Town. Factors contributing to providers’ decisions to suspend provision of the implant to women living with HIV included: inadequate initial and ongoing provider training; interpretation of NDoH communications about implant use with efavirenz; provider unwillingness to risk harming clients and concerns about professional liability; and other pressures related to provider capacity.

Conclusions

All South African women, including those living with HIV, should have access to the full range of contraceptive options for which they are medically eligible. Changing guidance should be initiated and communicated in consultation with primary-level providers and service beneficiaries. Guidance issued to providers needs to be clear and fully evidence-informed, and its correct interpretation and implementation facilitated and monitored. Guidance should be accompanied by provider training, as well as counselling messages and tools to support providers. Generalized retraining of providers in rights-based, client-centred family planning, and in particular implant provision for women with HIV, is needed. These recommendations accord with the right of women living with HIV to access the highest possible standard of sexual and reproductive healthcare, including informed contraceptive choice and access to the contraceptive implant.
Literature
1.
go back to reference Brown SS, Eisenberg L. Consequences of unintended pregnancy; 1995. Brown SS, Eisenberg L. Consequences of unintended pregnancy; 1995.
2.
go back to reference Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plan. 2010;41(4):241–50.CrossRef Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plan. 2010;41(4):241–50.CrossRef
3.
go back to reference Lince-Deroche N, et al. Achieving universal access to sexual and reproductive health services: the potential and pitfalls for contraceptive services in South Africa. South Afr Health Rev. 2016;2016(1):95–108. Lince-Deroche N, et al. Achieving universal access to sexual and reproductive health services: the potential and pitfalls for contraceptive services in South Africa. South Afr Health Rev. 2016;2016(1):95–108.
4.
go back to reference Ross, J. and J. Stover, Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Global Health: Science and Practice, 2013: p. ghs1300010. Ross, J. and J. Stover, Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Global Health: Science and Practice, 2013: p. ghs1300010.
5.
go back to reference World Health Organization, Quality of care in contraceptive information and services, based on human rights standards: a checklist for health care providers. 2017. World Health Organization, Quality of care in contraceptive information and services, based on human rights standards: a checklist for health care providers. 2017.
6.
go back to reference Wilcher R, Cates W. Reproductive choices for women with HIV. Bull World Health Organ. 2009;87(11):833–9.CrossRef Wilcher R, Cates W. Reproductive choices for women with HIV. Bull World Health Organ. 2009;87(11):833–9.CrossRef
7.
go back to reference Reynolds HW, et al. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis. 2006;33(6):350–6.CrossRef Reynolds HW, et al. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis. 2006;33(6):350–6.CrossRef
8.
go back to reference World Health Organization, PMTCT strategic vision 2010-2015: preventing mother-to-child transmission of HIV to reach the UNGASS and millennium development goals: moving towards the elimination of paediatric HIV, December 2009. 2010. World Health Organization, PMTCT strategic vision 2010-2015: preventing mother-to-child transmission of HIV to reach the UNGASS and millennium development goals: moving towards the elimination of paediatric HIV, December 2009. 2010.
9.
go back to reference UNAIDS, Country Fact Sheet: South Africa 2016. 2016. UNAIDS, Country Fact Sheet: South Africa 2016. 2016.
10.
go back to reference Statistics South Africa, South African demographic and health survey: key Indicator report. 2017. Statistics South Africa, South African demographic and health survey: key Indicator report. 2017.
11.
go back to reference Statistics South Africa, Mid-year population estimates. Statistics South Africa, 2017. Statistics South Africa, Mid-year population estimates. Statistics South Africa, 2017.
12.
go back to reference South African National Department of Health, National Contraception and Fertlity Planning Policy and Service Delivery Guidelines. 2012. South African National Department of Health, National Contraception and Fertlity Planning Policy and Service Delivery Guidelines. 2012.
13.
go back to reference South African National Department of Health, National Contraception Clinical Guidelines. 2012. South African National Department of Health, National Contraception Clinical Guidelines. 2012.
14.
go back to reference World Health Organization, Medical eligibility criteria wheel for contraceptive use. 2015: Geneva. World Health Organization, Medical eligibility criteria wheel for contraceptive use. 2015: Geneva.
15.
go back to reference Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol. 2011;117(3):705–19.CrossRef Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol. 2011;117(3):705–19.CrossRef
16.
go back to reference Pleaner M, et al. Lessons learnt from the introduction of the contraceptive implant in South Africa. SAMJ. 2017;107(11):933–8.CrossRef Pleaner M, et al. Lessons learnt from the introduction of the contraceptive implant in South Africa. SAMJ. 2017;107(11):933–8.CrossRef
17.
go back to reference Jacobstein R, Stanley H. Contraceptive implants: providing better choice to meet growing family planning demand. Global Health. 2013;1(1):11–7. Jacobstein R, Stanley H. Contraceptive implants: providing better choice to meet growing family planning demand. Global Health. 2013;1(1):11–7.
18.
go back to reference Adeagbo O, et al. Uptake and early removals of Implanon NXT in South Africa: perceptions and attitudes of healthcare workers. SAMJ. 2017;107(10):822–6.CrossRef Adeagbo O, et al. Uptake and early removals of Implanon NXT in South Africa: perceptions and attitudes of healthcare workers. SAMJ. 2017;107(10):822–6.CrossRef
19.
go back to reference Pillay D, et al. User perspectives on Implanon NXT in South Africa: a survey of 12 public-sector facilities. S Afr Med J. 2017;107(10).CrossRef Pillay D, et al. User perspectives on Implanon NXT in South Africa: a survey of 12 public-sector facilities. S Afr Med J. 2017;107(10).CrossRef
20.
go back to reference South African National Department of Health, Changes in the prescription of progestin subdermal implants (Implanon) in women who are taking enzyme iducing drugs such as efavirenz for HIV rifampicin for TB, and certain drugs used for epilepsy (carbamazepine, phenytoin, and phenobarbital): Dr Yogan Pillay (Deputy Director General), HIV/AIDS, TB, MCWH Directorate., H.a. south African National Department of health, TB, MCWH directorate., editor. 2014. South African National Department of Health, Changes in the prescription of progestin subdermal implants (Implanon) in women who are taking enzyme iducing drugs such as efavirenz for HIV rifampicin for TB, and certain drugs used for epilepsy (carbamazepine, phenytoin, and phenobarbital): Dr Yogan Pillay (Deputy Director General), HIV/AIDS, TB, MCWH Directorate., H.a. south African National Department of health, TB, MCWH directorate., editor. 2014.
21.
go back to reference Vieira CS, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. JAIDS J Acquir Immune Defic Syndr. 2014;66(4):378–85.CrossRef Vieira CS, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. JAIDS J Acquir Immune Defic Syndr. 2014;66(4):378–85.CrossRef
22.
go back to reference Perry SH, et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. Aids. 2014;28(5):791–3.CrossRef Perry SH, et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. Aids. 2014;28(5):791–3.CrossRef
23.
go back to reference South African National Department of Health, Technical brief: drug interactions with progestin subdermal implants. 2014. South African National Department of Health, Technical brief: drug interactions with progestin subdermal implants. 2014.
24.
go back to reference World Health Organization, Medical eligibility criteria for contraceptive use, fifth edition 2015. Full text and executive summary. 2015. World Health Organization, Medical eligibility criteria for contraceptive use, fifth edition 2015. Full text and executive summary. 2015.
25.
go back to reference Patel RC, et al. Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. Lancet HIV. 2015;2(11):e474–82.CrossRef Patel RC, et al. Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. Lancet HIV. 2015;2(11):e474–82.CrossRef
26.
go back to reference Pyra M, et al. Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS. 2015;29(17):2353–9.CrossRef Pyra M, et al. Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS. 2015;29(17):2353–9.CrossRef
27.
go back to reference Patel RC, et al. Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. J Int AIDS Soc. 2017;20(1).CrossRef Patel RC, et al. Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. J Int AIDS Soc. 2017;20(1).CrossRef
28.
go back to reference Morroni C, Bekker L-G, Rees H. Contraceptive implants and efavirenz-based ART: friend or foe? Lancet HIV. 2015;2(11):e454.CrossRef Morroni C, Bekker L-G, Rees H. Contraceptive implants and efavirenz-based ART: friend or foe? Lancet HIV. 2015;2(11):e454.CrossRef
29.
go back to reference Rees H, et al. Strengthening implant provision and acceptance in South Africa with the ‘any woman, any place, any time’approach: an essential step towards reducing unintended pregnancies. S Afr Med J. 2017;107(11):939–44.CrossRef Rees H, et al. Strengthening implant provision and acceptance in South Africa with the ‘any woman, any place, any time’approach: an essential step towards reducing unintended pregnancies. S Afr Med J. 2017;107(11):939–44.CrossRef
30.
go back to reference Lipsky, M., Street-level bureaucracy, 30th ann. Ed.: dilemmas of the individual in public service. 2010: Russell Sage Foundation. Lipsky, M., Street-level bureaucracy, 30th ann. Ed.: dilemmas of the individual in public service. 2010: Russell Sage Foundation.
31.
go back to reference Gilson, L., Lipsky’s street level bureaucracy. 2015. Gilson, L., Lipsky’s street level bureaucracy. 2015.
32.
go back to reference World Health Organization, Consolidated guideline on sexual and reproductive health and rights of women living with HIV: executive summary. 2017. World Health Organization, Consolidated guideline on sexual and reproductive health and rights of women living with HIV: executive summary. 2017.
33.
go back to reference World Health Organization, Ensuring human rights in the provision of contraceptive information and services: guidance and recommendations. 2014. World Health Organization, Ensuring human rights in the provision of contraceptive information and services: guidance and recommendations. 2014.
34.
go back to reference World Health Organization, Report on the public consultation to inform development of the framework on integrated people-centred health services. 2016, World Health Organization. World Health Organization, Report on the public consultation to inform development of the framework on integrated people-centred health services. 2016, World Health Organization.
35.
go back to reference The World Health Organisation, Transition to new anti-retroviral drugs in HIV programmes: Clinical and Programmatic Considerations. 2017. The World Health Organisation, Transition to new anti-retroviral drugs in HIV programmes: Clinical and Programmatic Considerations. 2017.
36.
go back to reference World Health Organization, Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2018, World Health Organization. World Health Organization, Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2018, World Health Organization.
Metadata
Title
Perspectives on contraceptive implant use in women living with HIV in Cape Town, South Africa: a qualitative study among primary healthcare providers and stakeholders
Authors
Anna Brown
Jane Harries
Diane Cooper
Chelsea Morroni
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-019-7312-1

Other articles of this Issue 1/2019

BMC Public Health 1/2019 Go to the issue